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ABSTRACT
Objective. Mental health problems are prevalent in youth with rheumatologic disease. 
Gaps in knowledge exist regarding their impact, as well as strategies for detection and 
effective treatment. To address these gaps, the Childhood Arthritis and Rheumatology 
Research Alliance (CARRA) Mental Health Workgroup developed and prioritized an 
agenda of research topics.
Methods. We systematically reviewed the literature and identified 5 major research 
domains in further need of study: (A) mental health burden and relationship to pediatric 
rheumatologic disease, (B) impact of mental health disorders on outcomes, (C) mental 
health awareness and education, (D) mental health screening, and (E) mental health 
treatment. Research topics within these areas were developed by workgroup leaders 
and refined by the workgroup. Members were surveyed to prioritize the topics by 
importance, feasibility of study, and actionability.
Results. Fifty-nine members (57%) completed the survey. Among the proposed 
research topics, 31/33 were rated as highly important and 4/33 were rated highly for 
importance, feasibility, and actionability. Topics rated most important related to (A) 
mental health burden and relationship to rheumatologic disease, and (B) the impact of 
mental health on outcomes. Topics rated most feasible and actionable were related to 
(D) mental health screening.
Conclusions. Addressing gaps in knowledge regarding mental health in youth with 
rheumatologic disease is essential for improving care. We have identified high priority 
research topics regarding mental health of pediatric rheumatology patients in need of 
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further investigation that are feasible to study and believed to lead to actionable results 
in patient care.
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INTRODUCTION
Depression, anxiety, and other mental health symptoms are common in children and 
adolescents with rheumatologic diseases, affecting at least 15-40% (1). However, 
significant deficiencies exist in access to mental health providers and the identification 
and treatment of these symptoms within pediatric rheumatology clinics (2, 3). Similar to 
youth with other chronic disease, evidence suggests that mental health symptoms in 
youth with rheumatologic disease are associated with poorer quality of life (4, 5), poor 
medication adherence (6), and possibly worse disease outcomes (7). Parents and 
siblings of youth with rheumatologic diseases also suffer from mental health symptoms, 
which are likely associated with their own adjustment to the affected child’s illness and 
associated mental and physical symptoms (8). Despite a growing appreciation that 
these symptoms are prevalent and detrimental, our understanding of the complex 
interplay between mental health symptoms and rheumatologic diseases is nascent. It is 
often unclear whether these symptoms arise as part of the inflammatory disease 
process itself, whether they are a reaction to the disease, or whether they are 
coincident. Furthermore, studies to asses strategies for adequate identification and 
effective treatment of mental health symptoms in this population are lacking (1). 
Our prior review of the literature on mental health symptoms in youth with rheumatologic 
diseases found that small, single-center, cross-sectional studies represent the bulk of 
evidence in the field and indicate that mental health symptoms are prevalent in this 
population (1, 9). These studies primarily focus on juvenile idiopathic arthritis (JIA) and 
systemic lupus erythematosus (SLE) and are limited in their representation of minority 
patients and sociodemographic information. Few longitudinal studies have been 
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conducted. Thus, significant gaps in our knowledge exist regarding risk factors for 
mental health symptoms, their long-term impact, strategies for mental health education, 
best screening practices, and effective treatment (1, 9). Few studies addressed 
potential roles for improving mental health care through integration of mental health 
services and educational opportunities for rheumatologists, despite growing evidence 
pointing to efficacy in general pediatrics and other pediatric chronic disease, such as 
diabetes and cystic fibrosis (10, 11). While our comprehension of the interactions 
between mental health and physical health in youth with chronic disease is expanding, 
the complicated relationship between mental health, inflammatory disease, and its 
treatment is less understood. Gaps in our knowledge exist regarding the potentially 
unique mental health needs of youth with rheumatologic disease, and optimal screening 
and treatment strategies for this population. Thus, to help advance our knowledge and 
coordinate the efforts of investigators committed to mental health research in pediatric 
rheumatology, the Mental Health Workgroup for the Childhood Arthritis and 
Rheumatology Research Alliance (CARRA) aimed to develop a prioritized research 
agenda. CARRA is an international research collaborative of pediatric rheumatologists, 
allied health professionals, patients, parents, and research associates. CARRA includes 
>550 pediatric rheumatology researchers and >95% of pediatric rheumatologists in the
US and Canada.
Prioritized research agendas promote clinically important and actionable research 
across disciplines to address areas of need (12-14). These are developed through 
literature reviews, in-person discussions, membership surveys, and Delphi methods to 
obtain consensus (13-15). The intent of developing a prioritized research agenda was to 
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promote clinically relevant, important, and feasible research efforts that address gaps in 
knowledge related to mental health of youth with rheumatologic disease, and that are 
likely to lead to changes in practice and improvements in care.
SUBJECTS AND METHODS
Prioritization methodology was adapted from the Prioritization Criteria Methods (PiCMe) 
of the Agency of Healthcare Research and Quality (AHRQ). This methodology includes: 
(1) systematically reviewing the literature, (2) determining gaps in evidence, (3)
developing research questions from evidence gaps, (4) ranking research questions, and 
(5) publishing research needs (16).
Systematic review of the literature on mental health in pediatric rheumatology was 
completed and published by members of the CARRA Mental Health Workgroup (1, 9). 
Through iterative discussions occurring over conference calls, a taskforce of 4 
workgroup members (AD, AK, MR, TR) reviewed the findings and developed consensus 
on 5 major research domains in need of further study: (A) mental health burden and 
relationship to pediatric rheumatologic disease, (B) impact of mental health disorders on 
outcomes, (C) mental health awareness and education, (D) mental health screening, 
and (E) mental health treatment. The taskforce then developed a list of 36 draft 
research topics within these domains based on the main identified knowledge gaps. 
These topics were discussed, refined, and revised at the CARRA Mental Health 
Workgroup Annual Meeting in April 2018, which 59 workgroup members attended, 
including pediatric rheumatologists, psychologists, social workers, patients, parents, 
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research coordinators, and industry members. Additional discussion and collection of 
feedback were conducted through email and a subsequent conference call to enable 
participation from workgroup members missing in attendance from the CARRA Annual 
Meeting. The resulting product of the iterative discussion and revision process was a list 
of 33 refined research topics that fell within the 5 research domains (Table 1). An online 
survey was created to prioritize the 33 topics based on 3 fields adapted from the AHRQ 
PiCMe: importance, feasibility, and actionability. Importance was defined as the 
relevance of the topic to advancing clinical care and research, considering existing 
knowledge. Feasibility was defined as the ease with which research could be conducted 
and completed. Actionability was defined as the ability to apply the results of research 
towards advancing clinical care.
The survey was distributed to all members of the workgroup email listserv (n=103). 
Respondents could choose to opt out of the survey (i.e. if not willing to participate or 
due to conflict of interest). Demographic and affiliation information was collected. We 
categorized participants into 3 subgroups of interest: i) more experienced (≥10 years in 
rheumatology) versus less experienced (<10 years) members, ii) rheumatologists 
(rheumatology attendings and rheumatology fellows) versus non-rheumatologists (all 
other workgroup members), and iii) among rheumatologists, research-focused (≥50% 
full-time-effort for research) versus not.
Respondents were asked to score each research topic on a 5-point scale for the 3 
fields: importance, feasibility, and actionability (1 = Low, 2 = Somewhat Low, 3 = 
Neutral, 4 = Somewhat High, 5 = High). Mean ranking scores were calculated. 
Research topics achieving mean ranking scores of ≥ 4 for importance, feasibility or 
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actionability were deemed “highly” important, feasible or actionable, respectively. 
Additionally, members were asked to provide an overall ranking (in consideration of 
importance, feasibility, and actionability) of research topics within each research 
domain. 
This study was approved by The Children’s Hospital of Philadelphia Institutional Review 
Board (IRB 18-015073) and survey responses were obtained with the participants’ 
informed consent.
Statistical analysis
Descriptive statistics were used to determine the mean and standard deviations of 
response scores for each research topic. Mean ranking scores and standard deviations 
were also calculated for the overall ranking of each of the different topics within domains 
to determine the highest ranked research topics for each of the 5 domains. Statistical 
analysis was performed using Stata 14 (StataCorp, College Station, Texas).
We conducted 3 comparison analyses by i) experience level, ii) rheumatologist status, 
and iii) level of research focus. To compare scores by each of these characterizations, 
we constructed mixed effects linear regression models with each field (importance, 
feasibility, actionability) as an outcome and with each subgroup characterization as a 
predictor. Random effects were specified for the respondent-specific intercept to 
account for intra-respondent correlations in the scores. Because patients/parents and 
mental health providers were two specific groups that were underrepresented in the 
workgroup membership and survey, we highlighted their responses on topic and domain 
importance and overall rankings of topics.  













































Seventy-three participants (71%) responded to the survey: 59 participants (57%) 
completed the survey, 6 participants (6%) opted out and 8 participants (8%) started but 
did not complete the survey. The majority of respondents were pediatric 
rheumatologists from academic centers, corresponding to the overall composition of the 
workgroup and CARRA membership. A relatively even distribution of members 
represented small centers (1-3 rheumatologists), medium centers (4-8), and large 
centers (9-14), and 53% of members were early-career (<10 years of experience). 
Among rheumatologists, 38% were research-focused. Non-rheumatologist participants 
included other medical providers, mental health providers, patients and parents, 
research coordinators, a sociologist, a member of industry and a health educator (Table 
2).
Highly important research topics
Among the proposed research topics 31/33 were rated as highly important (≥4 mean 
score) by the workgroup and all were rated relatively highly with mean scores ranging 
from 3.8-4.7 out of 5. Results of mixed effects models showed that none of the 
subgroups were independent predictors of importance scores. Overall, importance 
scores were similarly high in more and less experienced members 
(β[experienced]=0.11, p=0.4), rheumatologists and non-rheumatologists 
(β[rheumatologist]=0.05, p=0.7), and research-focused rheumatologists and other 
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rheumatologists (β[research-focused]=0.12, p=0.8). The highest scored topics for 
importance were in Domain A (mental health burden and relationship to pediatric 
rheumatologic disease, mean ± SD=4.5 ± 0.7) and Domain B (impact of mental health 
disorders on outcomes, mean ± SD=4.5 ± 0.7). These two domains achieved the 
highest mean importance scores in each member subgroup. Of specific interest in the 
non-rheumatologist subgroup were the 4 patient/parent representatives and the 3 
mental health providers. Among patients/parents, the highest mean importance scores 
across topics were in Domain A (mean ± SD=4.8 ± 0.3) and Domain D (mental health 
screening, mean ± SD=4.7 ± 0.4). Among mental health providers, the highest mean 
importance scores were in Domain B (mean ± SD=4.9 ± 0.2) and Domain D (mean ± 
SD=4.7 ± 0.2).
Highly feasible research topics
Regarding feasibility, 4/33 achieved mean scores ≥4 and determined to be highly 
feasible (mean scores ranged from 2.9-4.2). There were no significant differences seen 
between subgroups, though experienced members tended to give lower scores than 
less experienced (β[experienced]=-0.22, p=0.1) and research-focused rheumatologists 
tended to give higher scores than other rheumatologists (β[research-focused]=0.23, 
p=0.2). Overall, Domain D (mental health screening) topics were rated as most feasible 
(mean ± SD=3.9 ± 0.9). This domain achieved the highest mean feasibility scores in 
each member subgroup.
Highly actionable research topics
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Regarding actionability, 6/33 were rated as highly actionable (mean scores ranged from 
3.4 – 4.2), including all 4 of the topics rated as highly feasible (Figure 1). Overall, 
experienced members gave significantly lower actionability scores than less 
experienced members (β[experienced]=-0.33, p=0.02), while actionability scores 
between rheumatologists and non-rheumatologists were similar (β[rheumatologist]=-
0.002, p=1.0). Research-focused rheumatologists tended to give higher actionability 
scores compared to other rheumatologists, but this difference was not statistically 
significant (β[research-focused]=0.23, p=0.2). 
Overall, the topics rated as most actionable were in Domain D (mental health screening, 
mean ± SD=4.0 ± 0.9). Mean actionability scores were highest for Domain D in each 
subgroup except non-rheumatologists, who rated Domains A through D equally high (all 
with mean scores ± SD=3.9 ± 1.0). 
Summary of highest priority research topics
The 4 research topics achieving mean scores of ≥4 in all fields and thus determined to 
be highly important, feasible, and actionable were (in order of highest to lowest mean 
importance score): (A1) to determine the prevalence and incidence of mental health 
disorders in pediatric patients with rheumatologic disease, as well as socio-
demographic and disease-specific risk factors; (D1) to determine which mental health 
conditions are most important to screen, (D2) to determine the accuracy of mental 
health screening tools specifically for pediatric rheumatology disease populations, and 
(D4) to determine the barriers and facilitators to mental health screening the pediatric 
rheumatology setting (Figure 1). 
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For overall ranking priorities of research topics within each research domain, the top two 
for each of the 5 domains are shown bolded in Table 1. The priority rankings within 
domains by the overall workgroup yielded the same top two topics when we examined 
each subgroup, except for the subgroup of research-focused rheumatologists in the 
domains of (B) impact of mental health and (E) mental health treatment. Among 
research-focused rheumatologists, the topic (B2) “investigate the impact of mental 
health on long-term clinical outcomes” ranked more highly than (B3) “investigate the 
impact of mental health on health-related behaviors;” and the topic (E6) “investigate 
factors contributing to socio-cultural disparities in mental health care” outranked (E2) 
“determine whether adjustment/coping interventions around the time of diagnosis 
prevent the onset of major depression/anxiety or impact disease-related outcomes.”
Rankings by mental health providers yielded similar results to the overall group, with the 
exception of the domain of mental health education, in which they ranked topic (C3) 
“determine the impact of mental health education of rheumatology clinicians” above 
topic (C1) “understand the level of awareness for the importance of mental health 
among stakeholder groups.” Patients/parents ranked both of these topics as highest 
priority in this domain. Further differences among patients/parents to the overall group 
were in the domain of (A) mental health burden, in which they prioritized topic (A3) 
“investigate the relationship between mental health and rheumatologic disease 
treatments;” in the domain of (B) mental health impact, where they prioritized topic (B2) 
“investigate the impact of mental health on long-term clinical outcomes;” and in the 
domain of (D) mental health screening, in which they prioritized topic (D4) “determine 
barriers and facilitators to mental health screening the pediatric rheumatology setting.”
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DISCUSSION
We prioritized a research agenda for the CARRA Mental Health Workgroup by 
surveying a majority of workgroup participants to coordinate and promote research 
efforts in the most impactful areas defined by researchers, providers, and families with a 
vested interest in improving efforts in mental health care for youth with rheumatologic 
diseases. Four research topics were determined to be highly important, highly 
actionable, and highly feasible. These topics were (1) determine the prevalence and 
incidence of mental health disorders in pediatric patients with rheumatologic disease; 
(2) determine which mental health conditions are most important to screen; (3) 
determine the accuracy of mental health screening tools specifically for pediatric 
rheumatology disease populations; and (4) determine the barriers and facilitators to 
mental health screening in the pediatric rheumatology setting. There was general 
agreement between member subgroups regarding which research domains were of 
highest importance/ feasibility/ actionability. However, the domain of mental health 
screening had higher rankings among patients/parents and mental health providers, 
than in the overall membership. Within each domain there was more often consensus 
than disagreement between subgroups about the ranking of research topics.
Small, single-center, cross-sectional studies have established that mental health 
symptoms are prevalent in youth with rheumatologic disease. However, our review of 
the literature uncovered that minority populations and diseases outside SLE and JIA 
were underrepresented. With such few studies, it is difficult to draw conclusions about 
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the interaction between important socio-demographic factors or interactions with 
specific disease-related factors (1, 9). Larger scale, multi-center, studies will allow us to 
investigate socio-demographic risk factors and potential disparities in the identification 
of mental health symptoms across patient populations. Longitudinal studies are 
necessary to better understand the impact of disease-related factors and the nuances of 
mental health challenges across and within disease groups.
Topics related to mental health screening were rated most feasible and actionable and 
included 3 of the 4 highest priority topics. While mental health screening 
recommendations and guidelines exist for general pediatric populations (17, 18), 
generalizing guidelines for primary care practitioners to rheumatologists is problematic. 
This is due to the increased  prevalence of mental health conditions in youth with 
chronic conditions, the differing frequencies by which practitioners see patients, 
possible differences in mental health resources between pediatric subspecialty and 
general pediatric offices, and even differences in the relationships between patients and 
physicians among pediatric subspecialists and general pediatricians (1, 2, 19). Evidence 
supports systematic screening for mental health symptoms in adolescents with chronic 
illness (20). Screening approaches should also consider the known complex interplay 
between parental and child mental health and emotional adjustment to a chronic 
rheumatologic disease (21-23). Other chronic pediatric disease communities have 
developed specific screening tools (24, 25) and screening and treatment guidelines 
around mental health symptoms for their populations (11). Implementation studies in 
models of pediatric chronic disease clinics show that mental health screening is both 
feasible and clinically meaningful (10, 20). Yet specific guidelines regarding mental 
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health screening of youth with rheumatologic diseases do not yet exist and are needed 
to address the unique needs of this population.
Mixed methods studies, involving rheumatologists, mental health providers, patients and 
parents, have identified anxiety, depression, emotional adjustment to illness, and 
caregiver emotional support as areas of high importance to be screened for and 
addressed in the pediatric rheumatology setting (2). Given the paucity of mental health 
resources specifically identified for this patient population, further screening studies 
should focus on these critical areas. Validation of screening tools is needed across 
disease subpopulations. Future studies will need to investigate implementation 
strategies in pediatric rheumatology clinical settings and the development and testing of 
interventions such as peer support groups and cognitive behavioral therapy to address 
mental health.
While initial work to define barriers and facilitators to mental health screening in 
pediatric rheumatology clinics has identified that a lack of resources, guidelines, and 
education stand in the way of broadly implementing screening practices, preliminary 
data in SLE show feasibility and patient/parent acceptability of screening for anxiety and 
depression in pediatric rheumatology clinics (26). This work needs to be broadened to 
other rheumatologic diseases and implementation studies are needed to determine 
factors important to incorporating screening successfully into clinical practice. Quality 
improvement studies in pediatric rheumatology clinics are currently underway to 
optimize screening strategies to individual practices.
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The research topic prioritization by workgroup members exposed research topics that 
are highly important and actionable but were not deemed highly feasible. Among these 
are topics concerning the burden and relationship of mental health disorders on 
rheumatologic disease and the impact of mental health on clinical outcomes . Ways to 
help improve the feasibility of researching these topics include the development of 
resources in pediatric rheumatology research to address questions around mental 
health. Enhancing capacity for multidisciplinary collaboration between rheumatology 
researchers and mental health professionals in psychiatry, psychology, and social work 
will bring the necessary mental health expertise in the context of pediatric rheumatologic 
disease. Expanding the current longitudinal CARRA disease registry to include 
instruments to measure mental health will also improve the feasibility of this type of 
research. Furthermore, disease registries coupled to biorepositories and clinical data, 
such as the CARRA Registry, will help advance translational research to improve our 
understanding of pathophysiologic mechanisms that may help explain relationships 
between mental health symptoms and inflammation in rheumatologic disease.  
There are several limitations to this study. First, despite inclusion of non-
rheumatologists in the CARRA Mental Health Workgroup, the representation of mental 
health providers was minimal. This may be due to a lack of mental health providers 
connected to pediatric rheumatology clinics across the US (2). As their expertise is 
critical for multidisciplinary research to address mental health, further efforts are needed 
to recruit mental health professionals as integral members of research and care teams. 
Second, the representation of patients and parents was suboptimal, as their 
experiences with disease and as consumers of services provide essential perspectives 
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for developing clinically meaningful and relevant research in mental health. Current and 
future projects of the workgroup aim for better representation and engagement of 
patients and families as key advisors and participants on the research team (27). Given 
the few members in both of these subgroups, we cannot infer whether differences in 
rankings reported in this study are significant or truly representative. Third, the mental 
health research agenda is not representative of the entire CARRA membership. The 
prioritization process was limited to those involved in the Mental Health Workgroup. 
While this was an intentional design to gather input from those with knowledge and 
interest in mental health research, broader involvement of the CARRA membership will 
be necessary for successful collaborative projects including implementation studies of 
mental health guidelines in pediatric rheumatology.
Considering the challenges and limitations of investigating rare diseases, such as those 
in pediatric rheumatology, leveraging the interest of multiple stakeholders and 
identifying the most urgent and most feasible areas of research is imperative to foster 
successful and meaningful advances in research and care. By defining a prioritized 
research agenda to address the current gaps in knowledge that exist in our field 
regarding the mental health of youth with rheumatologic disease, we hope to improve 
care for this vulnerable patient population. These research topics address areas in need 
of improvement defined by our prior research (28) (Figure 2) and can direct specific 
research, clinical, and policy-making activities to improve care (Supplemental Table 1). 
The agenda developed here is intended to be an initial step in an iterative learning 
process requiring frequent reconsideration and revision. To improve upon the 
groundwork laid by the current agenda, we will need to expand partnerships with mental 
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health experts and patient families, to develop revised future research agendas that 
better incorporate their knowledge and perspectives. Topics sufficiently researched will 
be ‘checked off,’ making room for new topics that this agenda has yet to address. The 
success and the utility of the agenda in the future will be measured by whether the 
resulting studies lead to practice changes adopted by the larger pediatric rheumatology 
community and in further cycles of research to investigate whether those practices are 
producing improved outcomes for our patients.
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Figure 1. 
Research topics shown achieved ≥4 mean scores for actionability. Importance, feasibility, and 
actionability were scored on a 5-point scale (1 = Low, 2 = Somewhat Low, 3 = Neutral, 4 = Somewhat 
High, 5 = High).  Mean scores and standard deviations are shown.
Figure 2.
Responsiveness of CARRA Mental Health Workgroup prioritized research topics (Scopes of Research) to 
previously defined gaps in care in mental health for patients with pediatric rheumatologic diseases 
(Scopes of Action) (28). The bidirectional arrows represent the iterative process between research and 
implementation activities to achieve improved care.
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Table 1. Topics for Mental Health Research in Pediatric Rheumatology by Research Domain 
Defined by the CARRA Mental Health Workgroup
Domain: Research Topic:




(A1) Determine the prevalence and incidence of mental health disorders 
in pediatric patients with rheumatologic disease, as well as socio-
demographic and disease-specific risk factors.
(A2) Determine the relationship between mental health disorders, 
disease onset and disease course.
(A3) Investigate the relationship between mental health and 
rheumatologic disease treatments.
(A4) Investigate the biologic basis of mental health disorders.
(A5) Examine the impact of rheumatologic disease on neuropsychological 
development.
(B) Impact of mental
health disorders on
outcomes
(B1) Investigate the impact of mental health on clinical outcomes, such 
as disease activity.
(B2) Investigate the impact of mental health on long-term clinical 
outcomes, such as disease damage and mortality.
(B3) Investigate the impact of mental health on health-related 
behaviors, such as medication adherence.
(B4) Determine the impact of mental health on outcomes related to 
transition to adult care.
(B5) Investigate the impact of mental health on health care utilization and 
costs.
(B6) Investigate the impact of mental health on quality of life, social 
outcomes, education attainment, and work functioning.
(C) Mental health
awareness and education
(C1) Understand the level of awareness for importance of mental health 
among stakeholder groups.
(C2) Determine the impact of mental health education of 
patients/families on their perceived acceptability of mental health 
intervention.
(C3) Determine the impact of mental health education of rheumatology 
clinicians on their perceived feasibility/acceptability, and implementation 
of mental health practices/intervention.
(C4) Define gaps in knowledge for community behavioral health providers 
pertaining to specific mental health needs of patients with childhood-
onset rheumatologic disease and their families.
(C5) Determine the impact of stakeholder education on policy change for 
compensation of mental health screening/intervention.
(D) Mental health
screening
(D1) Determine which mental health conditions are most important to 
screen.
(D2) Determine the accuracy of mental health screening tools for 
identifying mental health conditions in specific pediatric rheumatology 
disease populations.
(D3) Determine the optimal timing, settings and process for mental health 
screening.
(D4) Determine barriers and facilitators to mental health screening in the 
pediatric rheumatology setting.
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(D5) Determine acceptability of mental health screening in pediatric 
rheumatology clinics for patients, caregivers, clinicians, and identify 
strategies to improve acceptability.
(D6) Determine the feasibility and sustainability of mental health 
screening in the pediatric rheumatology setting, including cost-
effectiveness, ethical and legal aspects.
(D7) Determine the impact of mental health screening on acceptability of 
mental health treatment for patients/caregivers.
(D8) Determine the efficacy of mental health screening in the pediatric 
rheumatology setting.
(D9) Determine the relationship between mental health screening and 
disease-related outcomes.
(E) Mental health 
treatment
(E1) Define barriers and facilitators to mental health treatment.
(E2) Determine whether adjustment/coping interventions around the 
time of diagnosis prevent the onset of major depression/anxiety or 
impact disease-related outcomes.
(E3) For different populations and different mental health disorders, 
determine which mental health treatment modalities are most 
efficacious.
(E4) Investigate the role of immunosuppressive therapy in treating mental 
health conditions in pediatric patients with rheumatologic disease.
(E5) Determine effective mental health treatment delivery options that 
differ by mode, provider, and setting.
(E6) Investigate factors contributing to socio-cultural disparities in mental 
health care and test interventions to reduce disparities.
(E7) Determine whether parent/caregiver-specific interventions improve 
mental health and disease-related outcomes.
(E8) Investigate the cost-effectiveness of mental health treatment in 
pediatric rheumatology setting.
Listed are the 33 refined research topics defined by the Childhood Arthritis and Rheumatology Research 
Alliance Mental Health Workgroup members. Bolded research topics are the topics that achieved the 
highest means for overall ranking of research topics within each domain. All research topics achieved 
mean “importance” ranking scores of ≥ 4 on a 5-point scale (1 = Low, 2 = Somewhat Low, 3 = Neutral, 4 
= Somewhat High, 5 = High), except for (E1) with mean score 3.9 and (E4) with mean score 3.8.
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Table 2. Demographics and Characteristics of CARRA Mental Health Workgroup Members 
Participating in the Research Agenda Prioritization Survey
CARRA Mental Health Workgroup Members Participating in 












    Attending:  28 (47%)
    Fellow: 14 (24%)
Nurse practitioner: 2 (3%)
Research coordinator: 6 (10%)
Parent/patient: 4 (7%)





















*Behavioral health provider: psychologist (2), social worker (1)
**Other: nephrologist (1), industry (1), other investigator (1), and non-profit health educator.
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Figure 1. Mean Scores for Highly Actionable Mental Health Research Topics in Pediatric Rheumatology
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Figure 2. Mental Health in Pediatric Rheumatology: Next Steps in Bridging the Gaps in Research and Care
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